OBJECTIVES: To analyze the healthcare resource utilization structure for oral vinorelbine versus IV chemotherapies in treating advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (mBC) from Chinese societal perspective. METHODS: Data of patients diagnosed with advanced NSCLC and mBC who were treated with oral vinorelbine or IV chemotherapy (either docetaxel, gemicitabine, paclitaxel, epirubicin, or pemetrexed) across 5 major cities in China were collected via chart review. Resource utilization and cost information for oral drug included travel/delivery expense, examination, premedication and others. For IV therapy, costs for drug preparation and administration, hospitalization/chair time, medical supplies, premedication, patients’ productivity loss and HCP labor cost were considered. Results were presented as a median total cost for delivering one dose of oral or IV therapy. RESULTS: CONCLUSIONS: Oral vinorelbine was associated with significant less delivery costs based on healthcare provider’s time, patient productivity loss and overall drug delivery costs compared to IV chemotherapy in treating advanced NSCLC and mBC.